GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Price-to-Free-Cash-Flow

Apollon Formularies (AQSE:APOL) Price-to-Free-Cash-Flow : N/A (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Price-to-Free-Cash-Flow?

As of today (2024-06-06), Apollon Formularies's share price is £8.0E-5. Apollon Formularies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00. Hence, Apollon Formularies's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Apollon Formularies's Price-to-Free-Cash-Flow or its related term are showing as below:

AQSE:APOL's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.885
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Apollon Formularies's Free Cash Flow per Share for the six months ended in Jun. 2023 was £0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 37.90% per year.

During the past 11 years, Apollon Formularies's highest 3-Year average Free Cash Flow per Share Growth Rate was 37.90% per year. The lowest was 37.90% per year. And the median was 37.90% per year.


Apollon Formularies Price-to-Free-Cash-Flow Historical Data

The historical data trend for Apollon Formularies's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Price-to-Free-Cash-Flow Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apollon Formularies's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Price-to-Free-Cash-Flow falls into.



Apollon Formularies Price-to-Free-Cash-Flow Calculation

Apollon Formularies's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=8.0E-5/0
=N/A

Apollon Formularies's Share Price of today is £8.0E-5.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollon Formularies's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Apollon Formularies  (AQSE:APOL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Apollon Formularies Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015